Switching to biological DMARDs versus cycling among JAK inhibitors in patients with rheumatoid arthritis and with inadequate response to JAK inhibitors: from FIRST registry
RMD Open. 2025 Jan 21;11:e004987
Miyazaki et al. investigated the efficacy and safety of switching to bDMARDs versus cycling among JAKis in RA patients with inadequate JAKi response. Cycling to another JAKi proved more effective in improving disease activity at 26 weeks compared to switching to a bDMARD, and both groups had similar safety profiles.
The study included 434 RA patients from the FIRST registry who began JAKi treatment, identifying that 31.8% had inadequate responses (JAKi-IR). Factors contributing to JAKi-IR included prior ineffective bDMARD use and suboptimal JAKi dosing. Efficacy and safety outcomes were analysed over 26 weeks following treatment changes.
Keywords:
